Health Condition 1: N40- Benign prostatic hyperplasia
Conditions
Interventions
Intervention1: Individualized Homoeopathic medicine: Intervention will be planned as administering indicated homoeopathic medicines selected on the basis of homoepathic principles in centesimal potenc
Sponsors
National Institute Of Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: a)Patients presenting symptoms of Benign Prostatic Hyperplasia with or without evidence of bladder outflow obstruction (AUASS more than 7) b)Patients suffering from cases of Benign Prostatic Hyperplasia diagnosed radiologically (USG-PELVIS) and ultrasonographical examination of Prostate weight more than 20g/20cc and RUV of more than 30ml c)Patients already undergoing regular therapy for BPH, provided the medications are stopped completely at least 2weeks prior study entry d)Male patients of all religions and of different socioeconomic status e)Patients with known but controlled systemic diseases f)Patients giving written consent to participate in the study
Exclusion criteria
Exclusion criteria: a)Patients with Serum Prostate specific antigen (PSA) more than 4 nmol/mL to rule out suspected prostatic malignancy b)Cases suffering from uncontrolled systemic illness or life-threatening conditions. c)Patient suffering from complete retention of urine for more than 24hrs. d)Patient with frequent urination or retention of urine due to systemic or neurological disorder. e)Patient suffering from neurogenic bladder or urethral stricture
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| On the basis of score obtained from the AMERICAN UROLOGICAL ASSOCIATION Symptom Score, cases according to intensity will be grouped into 1-7 mildly symptomatic 8-19 moderately symptomatic 20-35 severely symptomatic. Marked improvement â?? decrease of 70% or more in AUASS Moderate improvement â?? decrease of 50-70% in AUASS Mild improvement - decrease of less than 50% in AUASSTimepoint: At base line, at 3rd month and at 6th month | — |
Secondary
| Measure | Time frame |
|---|---|
| The reduction of size of prostate gland and RUV, will be recorded using USG-PELVISTimepoint: At base line and at 6th month | — |
Countries
India
Contacts
Public ContactDr Chintamani Nayak
National Institute Of Homoeopathy
Outcome results
None listed